Loading...
Loading...
CytRx Corporation
, a biopharmaceutical research and development
company specializing in oncology, today announced that aldoxorubicin, its more
potent version of the widely used chemotherapeutic agent doxorubicin,
demonstrated statistically significant efficacy (p<.0001) in the treatment of
rapidly growing human brain (glioblastoma) cancer in the brains of animals.
Complete results from this favorable confirmatory trial, which was conducted
in collaboration with Louisiana State University (LSU) School of Medicine,
will be presented at the European Society for Medical Oncology being held
September 29-October 1 2013 in Amsterdam.
“We are surprised and excited about the effectiveness demonstrated by
aldoxorubicin in this particularly difficult-to-treat cancer,” said Om
Prakash, Ph.D., the study's principal investigator and Research Professor of
Medicine, Stanley S. Scott Cancer Center, Louisiana State University Health
Sciences Center, New Orleans. “It has been well documented that doxorubicin,
although active against glioblastoma cancer cells in tissue culture, does not
cross the blood-brain barrier, the body's natural defense system protecting
the brain, to effectively treat patients with brain tumors. In fact, in our
study doxorubicin was no more effective than saline in suppressing
glioblastoma tumor growth. We have shown that aldoxorubicin uptake is confined
only to the tumor in the brain and does not enter normal brain tissue. Thus,
we would expect toxicity in the central nervous system to be negligible. Our
conclusion from this trial is that aldoxorubicin has the potential to safely
shrink glioblastoma tumors which could dramatically prolong the average
survival time in patients. We initially had observed a similar effect of
aldoxorubicin on glioblastoma in a preliminary study, and are quite pleased to
have confirmed the result in a larger, well-controlled study that included
native doxorubicin.”
Dr. Prakash's main focus of his research efforts in the last few years has
been to understand the pathogenesis and treatment of glioblastoma multiforme,
the most malignant and the most deadly type of brain tumor. He is the
corresponding author on several poster presentations in national/international
meetings. More recently, he is the first author on a publication, Gliomas and
Seizures in the Medical Hypothesis Journal (Prakash et al. 2012; 79:622).
“This trial produced remarkable results in a deadly cancer that virtually
always returns regardless of whether treated with surgery, radiation,
chemotherapy or a combination of methods,” said CytRx President and CEO Steven
A. Kriegsman. “Animals treated with aldoxorubicin survived on average more
than twice as long as those treated with saline or doxorubicin.
“Aldoxorubicin could provide an exciting new approach in how we attack brain
tumors. These outstanding results support our plan to initiate a Phase 2b
clinical trial with aldoxorubicin in patients with relapsed glioblastoma. We
remain on track with expanding our aldoxorubicin clinical development
activities and expect our progress to accelerate in the coming months and
year,” he added. If the data from the company's planned Phase 2b clinical
trial for glioblastoma are positive, it plans to file for breakthrough therapy
designation with the U.S. Food and Drug Administration, which could expedite
marketing approval for aldoxorubicin.
Aldoxorubicin has shown to be superior to doxorubicin in seven different tumor
types and animal models of cancer, including ovarian, lung, breast and
pancreatic cancer, as well as multiple myeloma, and has demonstrated activity
in human trials for the treatment of soft tissue sarcomas and other cancers.
Aldoxorubicin is the first drug candidate CytRx is developing based on a novel
linker technology that has proven ability to allow attachment of multiple
chemotherapeutic agents and is designed to provide both greater anti-cancer
activity and to mitigate the toxicity that limits these agents' use.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in